Patients with metastatic brain tumors (MBTs) require a multidisciplinary team-based approach to select the best treatment interventions. This podcast updates recommendations that address whether patients with parenchymal or leptomeningeal brain metastases benefit from treatment with molecular targeted agents regarding local control, overall survival (OS), progression-free survival (PFS), performance status, or reduction in central nervous system (CNS) side effects compared with standard management with chemotherapy, immune modulators, stereotactic radiosurgery (SRS), whole-brain radiation therapy (WBRT), and surgical resection.
Bradley Elder, MD
Navid Redjal, MD, FAANS
Kristin Huntoon, PhD, DO
Jawad Y. Fares, MD, MSc
